Alithea Bio to Join Industry Leaders at the 7th TCR-Based Therapies Summit in Boston

At Alithea Bio, we believe that “in-market success” for TCR-based cell and biologic therapies requires more than just clinical approval—it requires a mission-critical focus on durability, manufacturing efficiency, and commercial viability.

We are proud to announce that Alithea Bio will be participating in the 7th TCR-Based Therapies Summit, held from May 18–20, 2026, in Boston, MA.

This year’s summit arrives at a dynamic crossroads for the industry. While recent approvals have signaled a clear path to commercialization, the community is also addressing the deep-rooted challenges of development costs and long-term patient impact. The summit will cut through the noise, focusing on the full therapeutic landscape including TCR-T, TCR mimetics, TCR-TCEs, and TCR bispecifics.

Our representatives will join senior leaders from across the globe to explore how novel targets and advanced engineering can expand patient populations and ensure these therapies reach those who need them most.

Connect with Alithea Bio: If you are attending the summit and would like to learn more about our latest developments or discuss potential collaborations in the TCR space, we would love to connect.

Who: Alithea Bio

Event: 7th TCR-Based Therapies Summit

Location: Boston, MA

When: May 18–20, 2026

Stay tuned to our LinkedIn page for updates and insights from the event!